Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine

D. Edelstein, M. Brownlee

Research output: Contribution to journalArticlepeer-review

312 Scopus citations


Aminoguanidine-HCl inhibits the formation of advanced glycosylation end products (AGEs) in vitro and in vivo, but the mechanism by which this occurs has not been determined. Aminoguanidine inhibited glucose-derived AGE formation on RNase A by 67-85% at aminoguanidine-glucose molar ratios of 1:5 to 1:50 without affecting the concentration of Amadori products. Fast-atom- bombardment mass spectrometry of RNase peptides incubated with glucose alone or with glucose plus aminoguanidine showed that aminoguanidine inhibited the formation of AGEs without forming an adduct with glycosylated peptide. These data suggest that the primary mechanism of aminoguanidine action is reaction with Amadori-derived fragmentation products in solution. These findings are relevant to the potential clinical use of aminoguanidine in the prevention of diabetic complications.

Original languageEnglish (US)
Pages (from-to)26-29
Number of pages4
Issue number1
StatePublished - 1992

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine'. Together they form a unique fingerprint.

Cite this